Gardner Center for Parkinson's Disease

and Movement Disorders

234 Goodman Street, Cincinnati, Ohio 45219 | (866) 941-UCNI (8264)

Creatine Safety, Tolerability, & Efficacy in Huntington’s Disease

Study Number: 
CREST -E
Topic: 
Huntington's Disease
Pricipal Investigator: 
Fredy J Revilla
Ongoing: 
Ongoing
Place: 
Medical Arts Building
Overview: 

The primary aim of this study is to assess the effects of creatine monohydrate (HD-02) on the progression of functional decline in HD as measured by the change in the Total Functional Capacity (TFC) scale over 36 months. The study population includes subjects with early symptomatic Huntington’s disease.

Qualifications: 

Subjects ≥18 yrs, must have clinical features of HD and family history of HD; or CAG repeat expansion ≥ 36, in Stage I or II of illness (TFC ≥ 7), must be ambulatory and not requiring skilled nursing care. Exclusions include: Use of supplemental creatine or supplemental Coenzyme Q10 within 90 days. Screening labs: creatinine > 2.0 mg/dL, WBC < 3800/mm3, ALT > 2XULN.

Contact: 

For more information, please contact Maureen Gartner, RN, at maureen.gartner@uc.edu or (513) 558-0018.